ChemicalBook > Product Catalog >API >Antineoplastic agents >Antibiotics anticancer drugs >Pirarubicin

Pirarubicin

Pirarubicin Structure
CAS No.
72496-41-4
Chemical Name:
Pirarubicin
Synonyms
Therarubicin;PIRARUBICIN HYDROCHLORIDE;(8S,10S)-10-[(2S,4S,5S,6S)-4-Amino-6-methyl-5-[(2S)-oxan-2-yl]oxy-oxan-2-yl]oxy-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-9,10-dihydro-7H-tetracene-5,12-dione;(8S,10S)-10-[[3-Amino-2,3,6-trideoxy-4-O-[(2R)-tetrahydro-2H-pyran-2-yl]-a-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,12-naphthacenedione;1609rb;CS-702;THP-ADM;Pirabucin;Pirarubcin;THEPRUBICIN
CBNumber:
CB7315796
Molecular Formula:
C32H37NO12
Molecular Weight:
627.64
MOL File:
72496-41-4.mol
MSDS File:
SDS
Modify Date:
2023/7/3 17:51:04

Pirarubicin Properties

Melting point 188-192°C (dec.)
alpha D25 +175 ±25° (c = 0.2 in CHCl3)
Boiling point 834.7±65.0 °C(Predicted)
Density 1.51±0.1 g/cm3(Predicted)
storage temp. 2-8°C
solubility ethanol: soluble25mg/mL
form powder
pka 7.35±0.60(Predicted)
color Orange to Red
Stability Hygroscopic

SAFETY

Risk and Safety Statements

Symbol(GHS) 
GHS08
Signal word  Danger
Hazard statements  H340-H350-H360FD
Precautionary statements  P201-P202-P280-P308+P313-P405-P501
Hazard Codes  Xi
Risk Statements  36/37/38
Safety Statements  26-37/39
WGK Germany  3
RTECS  QI9296000
Toxicity LD50 i.v. in mice: 27.8 mg/kg (Umezawa, 1979)

Pirarubicin price More Price(2)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich(India) P8624 Pirarubicin ≥95% (HPLC) 72496-41-4 10MG ₹22299.5 2022-06-14 Buy
Sigma-Aldrich(India) P8624 Pirarubicin ≥95% (HPLC) 72496-41-4 25MG ₹53692 2022-06-14 Buy
Product number Packaging Price Buy
P8624 10MG ₹22299.5 Buy
P8624 25MG ₹53692 Buy

Pirarubicin Chemical Properties,Uses,Production

Description

Pirarubicin is a new anthracycline anticancer agent structurally related to doxorubicin. In acute leukemia, non-Hodgkin’s lymphoma, breast and ovariail carcinoma, pirarubicin is reportedly superior to doxorubicin and better tolerated. Its major side-effect appears to be myelosuppression, mainly in the form of leucopenia, which is potentially dose-limiting.

Chemical Properties

Red Solid

Pirarubicin Preparation Products And Raw materials

Raw materials

Preparation Products

Global( 259)Suppliers
Supplier Tel Country ProdList Advantage Inquiry
SynZeal Research Pvt Ltd +1 226-802-2078 Gujarat, India 6522 58 Inquiry
Pharmaffiliates Analytics and Synthetics P. Ltd +91-172-5066494 Haryana, India 6773 58 Inquiry
Pharma Affiliates 172-5066494 Haryana, India 6761 58 Inquiry
CLEARSYNTH LABS LTD. +91-22-45045900 Hyderabad, India 6351 58 Inquiry
Hebei Mojin Biotechnology Co., Ltd +8613288715578 China 12450 58 Inquiry
ATK CHEMICAL COMPANY LIMITED +undefined-21-51877795 China 32760 60 Inquiry
career henan chemical co +86-0371-86658258 +8613203830695 China 29894 58 Inquiry
Hebei Guanlang Biotechnology Co., Ltd. +86-19930503282 China 8822 58 Inquiry
Xiamen AmoyChem Co., Ltd +86-592-6051114 +8618959220845 China 6387 58 Inquiry
BOC Sciences +1-631-485-4226 United States 19553 58 Inquiry

Pirarubicin Spectrum

THP-ADM THEPRUBICIN (8s-cis)-droxyacetyl)-1-methoxy Tepirubicin Therarubiein THP-adriamycin 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-alpha-L- lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- (8S)-10α-[[3-Amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8β-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione (8S,10S)-10α-[[3-Amino-4-O-(tetrahydro-2H-pyran-2-yl)-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8β-hydroxyacetyl-1-methoxy-5,12-naphthacenedione Pirarubicin(THP-AdriaMycin) (7S,9S)-7-((2R,4S,5S,6S)-4-amino-6-methyl-5-((R)-tetrahydro-2H-pyran-2-yloxy)-tetrahydro-2H-pyran-2-yloxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione PIRARUBICIN 1609rb 4’-o-tetrahydropyranyladriamycin 4’-o-tetrahydropyranyldoxorubicin 5,12-naphthacenedione,10-((3-amino-2,3,6-trideoxy-4-o-(tetrahydro-2h-pyran-2-y l)-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hy Pirarubicin(BICINS) (8S,10S)-10-[[3-Amino-2,3,6-trideoxy-4-O-[(2R)-tetrahydro-2H-pyran-2-yl]-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,12-naphthacenedione Pinorubicin Pirabucin 5,12-Naphthacenedione, 10-3-amino-2,3,6-trideoxy-4-O-(2R)-tetrahydro-2H-pyran-2-yl-.alpha.-L-lyxo-hexopyranosyloxy-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (8S)-10-[(2S,4S,5S,6S)-4-amino-6-methyl-5-[(2R)-oxan-2-yl]oxy-oxan-2-yl]oxy-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-9,10-dihydro-7H-tetracene-5,12-dione CS-702 Pirarubcin 5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-[(2R)-tetrahydro-2H-pyran-2-yl]-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)- Pirarubicin USP/EP/BP (8S,10S)-10-(((2R,4S,5S,6S)-4-Amino-6-methyl-5-(((R)-tetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione PIRARUBICIN HYDROCHLORIDE Therarubicin (8S,10S)-10-[[3-Amino-2,3,6-trideoxy-4-O-[(2R)-tetrahydro-2H-pyran-2-yl]-a-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,12-naphthacenedione (8S,10S)-10-[(2S,4S,5S,6S)-4-Amino-6-methyl-5-[(2S)-oxan-2-yl]oxy-oxan-2-yl]oxy-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-9,10-dihydro-7H-tetracene-5,12-dione Pirarubicin Topoisomerase II inhibitor ab142734 Famoxadone Impurity 14 THP-Doxorubicin Theprubicin|||THP 72496-41-4 C32H37NO12 Inhibitors API Intermediates & Fine Chemicals Pharmaceuticals Chiral Reagents